Prior to joining Geron, Mr. Samuels served as Chief Legal Officer and Chief Compliance Officer of Prilenia Therapeutics, Inc., a clinical-stage biotechnology company focused on novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, from March to May 2023. Before that, he served as the Senior Vice President, General Counsel of BeiGene, Ltd., from May 2017 to July 2022, where he built a large, global legal and compliance team, oversaw launches of three internally developed drug products in the U.S., Europe and China and development of a global healthcare compliance program, and led key strategic transactions with Amgen, Inc., Novartis AG and Celgene (now Bristol Myers Squibb).
Prior to BeiGene, Mr. Samuels was assistant general counsel and then acting general counsel at ARIAD Pharmaceuticals, Inc., where he managed the company’s legal affairs, including SEC compliance and corporate governance and key licensing and distribution agreements prior to ARIAD’s acquisition by Takeda. Mr. Samuels also practiced law for 17 years in the corporate and life sciences practices at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., a highly regarded national law firm. Mr. Samuels received his B.A. in philosophy from Cornell University and his J.D. from George Mason University School of Law.
What is Scott Alan Samuels' net worth?
The estimated net worth of Scott Alan Samuels is at least $36,020.70 as of February 27th, 2025. Mr. Samuels owns 26,682 shares of Geron stock worth more than $36,021 as of April 21st. This net worth evaluation does not reflect any other assets that Mr. Samuels may own. Learn More about Scott Alan Samuels' net worth.
How do I contact Scott Alan Samuels?
The corporate mailing address for Mr. Samuels and other Geron executives is 919 EAST HILLSDALE BOULEVARD SUITE 250, FOSTER CITY CA, 94404. Geron can also be reached via phone at (650) 473-7700 and via email at investor@geron.com. Learn More on Scott Alan Samuels' contact information.
Has Scott Alan Samuels been buying or selling shares of Geron?
Scott Alan Samuels has not been actively trading shares of Geron within the last three months. Most recently, on Thursday, February 27th, Scott Alan Samuels bought 15,000 shares of Geron stock. The stock was acquired at an average cost of $1.61 per share, with a total value of $24,150.00. Following the completion of the transaction, the executive vice president now directly owns 26,682 shares of the company's stock, valued at $42,958.02. Learn More on Scott Alan Samuels' trading history.
Who are Geron's active insiders?
Geron's insider roster includes Faye Feller (Executive Vice President, Chief Medical Officer), Andrew Grethlein (xecutive Vice President, Chief Operating Officer), V. Lawlis (Director), Susan Molineaux (Director), Elizabeth O'Farrell (Director), Scott Samuels (Executive Vice President, Chief Legal Officer and Secretary), John Scarlett (CEO), and Robert Spiegel (Director). Learn More on Geron's active insiders.
Are insiders buying or selling shares of Geron?
During the last twelve months, Geron insiders bought shares 2 times. They purchased a total of 27,500 shares worth more than $46,150.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 1,562,248 shares worth more than $6,808,003.88. The most recent insider tranaction occured on February, 27th when EVP Scott Alan Samuels bought 15,000 shares worth more than $24,150.00. Insiders at Geron own 3.1% of the company.
Learn More about insider trades at Geron. Information on this page was last updated on 2/27/2025.
